Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp (NQ: LEXX )

1.580 +0.080 (+5.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Lexaria Bioscience Corp

< Previous 1 2 3 4 5 Next >
Lexaria Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Lexaria Bioscience Marks Great Start to its 2022 R&D Programs
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria received independent review... 
Via Benzinga
Lexaria Bioscience Comments on Study Examining Cannabinoids and SARS-CoV-2
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a... 
Via Benzinga
Lexaria Bioscience Leveraging DehydraTECH(TM) for More Effective Oral Medicine
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX... 
Via Benzinga
Lexaria Bioscience Celebrates Productive Year for Blood Pressure Drug Solution
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience’s ongoing... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria has received approval from the... 
Via Benzinga
Why Lexaria Shares Are Rising Today
Lexaria Bioscience Corp (NASDAQ:LEXX) is trading higher We... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers ContraFect (NASDAQ:CFRX) stock mo... 
Via Benzinga
Lexaria Bioscience Increases Investor Visibility with SRAX
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The strategic move to incorporate... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers ContraFect (NASDAQ:CFRX) stock in... 
Via Benzinga
Lexaria Bioscience Announces Approval from Independent Review for DehydraTECH-CBD Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has received Independent Review Board (“IRB”) approval for its planned DehydraTECH-... 
Via Benzinga
Lexaria Bioscience Expects Study Results to Show Patented Tech's Value in Treating Hypertension
Lexaria Bioscience is preparing to file an Investigational New Drug application with the U.S. Food and Drug Administration for its patented technology’s use in treating... 
Via Benzinga
Lexaria Bioscience Announces Major Discovery; Increasing Effectiveness of Orally Administered CBD
In a recent human clinical trial, HYPER-H21-2, DehydraTECH-CBD reduced arterial stiffness, potentially broadening Lexaria’s application’s ability to treat... 
Via Benzinga
Lexaria's DehydraTECH(TM) CBD Found to Reduce Arterial Stiffness in Study
Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood... 
Via Benzinga
Lexaria Bioscience Committed to Innovation and Improving Quality of Life
Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021 The event came right after the company announced human clinical... 
Via Benzinga
Lexaria's Upcoming R&D Programs Targeting Global Markets Exceeding $160B
Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022 The programs are designed to explore the ability of the company’s... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares surged 84.1% to close at $19.11 on Wednesday. Insignia Systems recently announced the commencement of a formal process to... 
Via Benzinga
Lexaria Bioscience Featured in Virtual Coverage of Benzinga's Small Cap Conference
Lexaria Bioscience (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company leverages its patented technology, DehydraTECH(TM), to improve the delivery of... 
Via Benzinga
35 Stocks Moving In Wednesday's Mid-Day Session
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement of a formal process to explore strategic options... 
Via Benzinga
Read Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket?
Lexaria Bioscience Corp (NASDAQ: LEXX) has issued follow-up results from human clinical study HYPER-H21-2 of DehydraTECH-processed cannabidiol (CBD). The data... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Lexaria Bioscience (NASDAQ:LEXX) shares increased by 30.28% to $6.41 during Wednesday's pre-market session. The company's market cap stands at $36.7... 
Via Benzinga
Lexaria Bioscience Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
Lexaria Bioscience Corp. (NASDAQ: 
Via Benzinga
Lexaria's DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
Lexaria Bioscience Corp 
Via Benzinga
Lexaria Bioscience's DehydraTECH(TM) Drug Delivery Tech Finding Multiple Applications
Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursu... 
Via Benzinga
Lexaria Bioscience Announces 2022 DehydraTECH(TM) R&D Programs
Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions The program builds... 
Via Benzinga
Lexaria Bioscience Corp. Embarks on Ambitious Hypertension Clinical Study
Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and its most ambitious yet This study builds on the HYPER-H21-1 and HYPER-H21-2 findings,... 
Via Benzinga
Lexaria Expands 2022 R&D Programs to Evaluate Alzheimer's, Diabetes
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs... 
Via Benzinga
Lexaria Bioscience Corp. Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology's Efficacy in Reducing/Inhibiting Seizure Activity
Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD h... 
Via Benzinga
Lexaria Bioscience Corp. to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced a significant new study to expand its hypertension clinical program. In addition... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.